OncoMatch/Clinical Trials/NCT05491512
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer
Is NCT05491512 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Cisplatin and Carboplatin for hpv.
Treatment: Cisplatin · Carboplatin · 5-fluorouracil — The purpose of this study is to find out if lower doses of radiation may help reduce the side effects of radiation therapy in combination with standard-of-care chemotherapy in people with HPV-positive throat cancer. The chemotherapy drugs used in this study include cisplatin, carboplatin, and 5-fluorouracil (5- FU), paclitaxel and abraxane- (Albumin-bound Paclitaxel).
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: head and neck radiation therapy
Subjects with prior head and neck radiation therapy
Cannot have received: systemic chemotherapy for the study cancer
Exception: prior chemotherapy for a different cancer is allowable
Prior systemic chemotherapy for the study cancer; note that prior chemotherapy for a different cancer is allowable
Lab requirements
Blood counts
WBC 2 K/mcL; ANC 1,000 cells/mm3; Platelets 100,000 cells/mm3; Hemoglobin 8.0 g/dl (transfusion or other intervention to achieve Hgb 8.0 g/dl is acceptable)
Kidney function
Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula
Liver function
Bilirubin < 2 mg/dl; AST or ALT < 3 x the upper limit of normal (exceptions can be made with PI and/or Co-PI approval for higher Bilirubin such as Gilbert's Syndrome)
Adequate hematologic function within 30 days prior to registration, defined as follows: White Blood Count (WBC) 2 K/mcL; Absolute neutrophil count (ANC) 1,000 cells/mm3; Platelets 100,000 cells/mm3; Hemoglobin 8.0 g/dl; Note: The use of transfusion or other intervention to achieve Hgb 8.0 g/dl is acceptable. Adequate renal function within 30 days prior to registration, defined as follows: Serum creatinine < 1.5 mg/dl or creatinine clearance (CC) 50 ml/min determined by 24-hour collection or estimated by Cockcroft-Gault formula. Adequate hepatic function within 30 days prior to registration, defined as follows: Bilirubin < 2 mg/dl; AST or ALT < 3 x the upper limit of normal. Note: Exceptions can be made with PI and/or Co-Pi approval for patients to enroll on trial with a higher Bilirubin level such as Gilbert's Syndrome.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities) · Basking Ridge, New Jersey
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) · Middletown, New Jersey
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) · Montvale, New Jersey
- Memorial Sloan Kettering Cancer Center at Suffolk-Commack (Limited Protocol Activities) · Commack, New York
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) · Harrison, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify